At Otsuka, our purpose is to defy limitation, so that others can too. Otsuka established a presence in the U.S. in 1973 and today its U.S. affiliates include Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) and Otsuka America Pharmaceutical, Inc. (OAPI). These two companies’ 1,700 employees in the U.S. develop and commercialize medicines in the areas of mental health, nephrology and digital innovation using cutting-edge technology to address unmet healthcare needs.
Kabir Nath, MA, MBA
PRESIDENT & CEO, Otsuka North America Pharmaceutical Business
Kabir has nearly thirty years of broad international biopharmaceutical and medical device experience. He has shaped strategy and delivered results in complex, challenging business environments at country, regional, and global levels.
Kabir joined Otsuka in March 2016 to head all commercial operations within our North American pharmaceutical businesses. In March 2020, Kabir was appointed Senior Managing Director, Global Pharmaceutical Business, OPC, with overall operational leadership for the global pharma business, overseeing the regions of North America, Europe, Japan, and the rest of Asia. He continues to oversee the North American business in parallel.